MetaCap

AC Immune SA (ACIU) vs BioAge Labs (BIOA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AC Immune SA (ACIU) has outperformed BioAge Labs (BIOA) over the past year, losing 35.0% versus a loss of 50.5%. BioAge Labs is the larger company by market cap ($196.7 million vs $193.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACIU-35.00%BIOA-50.52%
+202%+70%-63%
Nov 21, 20251 yearNov 20, 2026
ACIU-48.00%BIOA-79.62%
+25%-32%-90%
Sep 23, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACIU versus BIOA key metrics
MetricACIUBIOA
Share price$1.95$4.28
Market cap$193.88M$196.67M
1-day change-8.45%-9.13%
YTD return-37.90%-67.65%
1-year return-35.00%-50.52%
5-year return-62.28%—
Forward P/E2.84—
EPS (TTM)$-0.44$-2.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.99M
Net income (latest FY)—$-80.61M
Operating margin—-1031.46%
Net margin—-896.11%
52-week high$3.90$25.96
52-week low$1.93$4.24
Distance from 52-week high-50.00%-83.51%
Analyst consensusstrong_buybuy
Avg. price target upside+331.28%+572.43%
Average volume198.81K740.06K
Shares outstanding99.43M45.95M
Employees9060
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACIU has outperformed BIOA by 15.5 percentage points over the past year.

About AC Immune SA

ACIU stock →

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees

About BioAge Labs

BIOA stock →

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

ACIU vs BIOA FAQ

Which is bigger, AC Immune SA or BioAge Labs?

BioAge Labs (BIOA) is larger, with a market capitalization of $196.67M compared with $193.88M for AC Immune SA (ACIU).

Which stock has performed better over the past year, ACIU or BIOA?

ACIU returned -35.00% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.

Are AC Immune SA and BioAge Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons